Compare Cytokinetics Inc (CYTK) vs Peloton Interactive Inc (PTON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Peloton Interactive Inc — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Peloton Interactive Inc trades at $4.92 (market cap $2.16B). The key difference: Cytokinetics Inc is far larger — about 4× Peloton Interactive Inc's market cap, and Peloton Interactive Inc is more actively traded (11,369,487 versus 2,594,626). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Peloton Interactive Inc for 37 Days on average.
| CYTK | PTON | |
|---|---|---|
Market Cap | $8.62B | $2.16B |
Volume | 2,594,626 | 11,369,487 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $7.86 |
52-Week Low | $54.76 | $3.71 |
Typical Hold Time | 19 Days | 37 Days |
Enterprise Value | $8.72B | $2.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Peloton (PTON) trades at $4.85, down 0.41% on the day, as the stock remains under technical pressure with bearish moving average signals. Fundamentally, the company achieved its first full-year net profit in fiscal 2026 with a 2.58% margin, while revenue declined to $2.4B. Recent product launches include a new foldable Tread Flex treadmill and AI-powered coaching features, signaling continued turnaround efforts under CEO Peter Stern's leadership.
The outlook remains challenged despite profitability improvements, with analyst consensus pointing to significant upside (target $8.00) but technical weakness and declining subscriber counts creating headwinds. Key risks include execution of the turnaround strategy, competitive pressure in connected fitness, and high debt levels, though cost-cutting measures show early success.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →
